跳至主要内容
临床试验/EUCTR2016-003168-37-DE
EUCTR2016-003168-37-DE进行中(未招募)1 期

Therapeutic Iloprost for the treatment of Acute Respiratory Distress Syndrome (ARDS) (the ThIlo-Trial): a prospective, randomized, multicenter phase II study - Thllo

niversity Tuebingen0 个研究点目标入组 150 人开始时间: 2018年11月29日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1.PaO2/ FiO2 = 300
  • 2.Bilateral opacities on frontal chest radiograph, and
  • 3.requirement for positive pressure ventilation via an endotracheal tube or non-invasive ventilation
  • 4.no clinical signs of left atrial hypertension detected via echocardiography, or if measured, a Pulmonary Arterial Wedge Pressure (PAOP) less than or equal to 18 mmHg.
  • 5.The term acute onset” is defined as following: the duration of the hypoxemia criterion (#i) and the chest radiograph criterion (#ii) must be = 28 days at the time of randomization. Patients must be enrolled within 48 hours of onset of ARDS and no later than 7 days from the initiation of mechanical ventilation.
  • 6.Subject’s Age = 18 years
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 80
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 70

排除标准

  • 1.Subject’s Age < 18 years
  • 2.More than 7 days since initiation of mechanical ventilation
  • 3.more than 48 hours since onset of ARDS
  • 4.Patient, surrogate or physician not committed to full intensive care support.
  • 5.Positive Pregnancy test at the time of screening.
  • 6.Contraindications for Iloprost: Conditions where the effects of Iloprost on platelets might increase the risk of hemorrhage (e.g. active peptic ulcers, trauma, intracranial hemorrhage), severe coronary heart disease, myocardial infarction (within the last 6 months), decompensated heart failure, severe arrhythmias, unstable angina pectoris, pulmonary arterial hypertension caused by occlusion of pulmonary veins, cerebrovascular events (e.g. transient ischemic attack, stroke) within the last 3 months, congenital or acquired valvular defects with clinically relevant myocardial function disorders not related to pulmonary hypertension, patients taking Direct Thrombin Inhibitors within previous 24h before study randomization.
  • 7.Patients having NO Therapy within the previous 24h before study randomization
  • 7.8.Patients who received Iloprost treatment for any indication within 48 hours prior to the enrolment into the clinical trial
  • 8.9.Patients dependent on the sponsor, investigator and their employees, as well as persons dependent on the manufacturer of the investigational drug
  • 9.10.Subject (male or female) is not willing to use highly effective methods of contraception according to the Clinical trial fertility group” recommendations (http://www.hma.eu/fileadmin/dateien/Human_Medicines/01About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf) during treatment and for 28 days (male or female) after the end of treatment (adequate: combined hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasoing system, bilateral tubal occlusion, vasectomized partner1, sexual abstinence2).

研究者

发起方
niversity Tuebingen

相似试验